Comparison of Fulvestrant (FASLODEXâ„¢) 250 mg and 500mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:b152583dbbbb2ec2692fe4c2177b7001' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: UPDATE cache_filter SET data = '<p>The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with estrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.</p>\n', created = 1283576048, expire = 1283662448, headers = '', serialized = 0 WHERE cid = '1:b152583dbbbb2ec2692fe4c2177b7001' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:030cdb3d891743016ea7db276256a751' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: UPDATE cache_filter SET data = '<p>A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Fulvestrant (FASLODEX™) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Adv</p>\n', created = 1283576048, expire = 1283662448, headers = '', serialized = 0 WHERE cid = '1:030cdb3d891743016ea7db276256a751' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:cc7819055cde3194bb3b136bad5cf58d' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: UPDATE cache_filter SET data = '<p> </p>\n', created = 1283576048, expire = 1283662448, headers = '', serialized = 0 WHERE cid = '1:cc7819055cde3194bb3b136bad5cf58d' in /persistent/html/includes/cache.inc on line 109.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:4f211f517f3e3cf655099cbbc400d2e1' in /persistent/html/includes/cache.inc on line 26.
user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired
query: UPDATE cache_filter SET data = '<p>Inclusion Criteria:\n<ul>\n<li>Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor</li>\n<li>Requiring hormonal treatment</li>\n<li>Postmenopausal women defined as a woman who has stopped having menstrual periods</li>\n<li>Evidence of positive estrogen receptor hormone sensitivity</li>\n<li>Written informed consent to participate in the trial</li>\n</ul>\n</p><p> Exclusion Criteria:\n<ul>\n<li>Treatment with an investigational or non-approved drug within one month</li>\n<li>An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures</li>\n<li>A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor oil)</li>\n<li>Treatment with more than one regimen of chemotherapy for advanced breast cancer</li>\n<li>Treatment with more than one regimen of hormonal treatment for advanced breast cancer</li>\n</ul>\n</p>', created = 1283576048, expire = 1283662448, headers = '', serialized = 0 WHERE cid = '1:4f211f517f3e3cf655099cbbc400d2e1' in /persistent/html/includes/cache.inc on line 109.
Trial phase:
Phase III
Recruitment status:
Active, not recruiting
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with estrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.